These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A combination therapy for cystic fibrosis. Brodsky JL; Frizzell RA Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363 [TBL] [Abstract][Full Text] [Related]
24. New cystic fibrosis drug paves the way for orphan diseases. Cooney D Lancet Respir Med; 2013 Apr; 1(2):104. PubMed ID: 24429084 [No Abstract] [Full Text] [Related]
26. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242 [No Abstract] [Full Text] [Related]
27. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Jones AM; Barry PJ Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414 [No Abstract] [Full Text] [Related]
29. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519 [TBL] [Abstract][Full Text] [Related]
30. Cystic fibrosis in an era of genomically guided therapy. Barrett PM; Alagely A; Topol EJ Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736 [TBL] [Abstract][Full Text] [Related]
31. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Sawicki GS; Dasenbrook E; Fink AK; Schechter MS Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026 [TBL] [Abstract][Full Text] [Related]
32. Aquagenic wrinkling of the palms in a patient with cystic fibrosis. Grasemann H; Ratjen F; Solomon M N Engl J Med; 2013 Dec; 369(24):2362-3. PubMed ID: 24328486 [No Abstract] [Full Text] [Related]
33. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
34. PharmGKB summary: very important pharmacogene information for CFTR. McDonagh EM; Clancy JP; Altman RB; Klein TE Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096 [No Abstract] [Full Text] [Related]
35. Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis "wonder drug". Rachul C; Toews M; Caulfield T J Cyst Fibros; 2016 Sep; 15(5):624-9. PubMed ID: 27150823 [TBL] [Abstract][Full Text] [Related]
37. Lung clearance index response in patients with CF with class III CFTR mutations. Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510 [No Abstract] [Full Text] [Related]